Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Re-Evaluating Growth Opportunities In Vascular Interventional Device Markets

Executive Summary

Manufacturers are finding it harder to innovate in the vascular interventional device arena as market and regulatory pressures take their toll. New coronary drug-eluting stents face a difficult challenge with the high bar now set by existing devices, and there have been several recent disappointments in the areas of renal denervation, drug-coated balloons, and renal artery stenting; still there are areas of opportunity that continue to look promising, with bioresorbable stents offering perhaps the best prospect among vascular therapies for future blockbuster status.

You may also be interested in...



Emerging PAD Devices Impress With New Trial Results, Funding

Two very different ways to treat peripheral arterial disease – lithotripsy combined with angioplasty and nitinol Tack implants – have demonstrated impressive six-month and one-year clinical results, respectively, and companies with these devices continue to attract funding.

Peripheral Artery Disease: Treatments And Diagnostics Poised For Growth

The market for peripheral vascular interventions and diagnostics is poised for significant growth in the years ahead, driven by an aging population and the growing incidence of peripheral vascular disease, along with new technological developments such as drug-eluting balloons, which are inching closer to regulatory approval in the US.

TAVR Market: Next-Generation Devices Seek To Optimize Outcomes

The market opportunity for TAVR is significant, with 2013 sales totaling $303.4 million in the US and $765 million outside the US, and those numbers are expected to grow to an estimated $1.29 billion and $1.63 billion, respectively, by 2018. Edwards and Medtronic dominate the worldwide market at present, but other companies are expected to make inroads with next-generation devices designed to optimize outcomes.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

LL029263

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel